Mark T. Osterman

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Konstantinos Papamichael, Karen A. Chachu, Ravy K. Vajravelu et al. · Clinical Gastroenterology and Hepatology · 2017 · 218 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Mark T. Osterman, William J. Sandborn, Jean–Frédéric Colombel et al. · Gastroenterology · 2013 · 189 citations

Adalimumab Combination Therapy, Medicine, Immunology +7

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

Frank I. Scott, Ronac Mamtani, Colleen Brensinger et al. · JAMA Dermatology · 2015 · 171 citations · Full text

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease

James D. Lewis, Frank I. Scott, Colleen Brensinger et al. · The American Journal of Gastroenterology · 2018 · 140 citations · Full text

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

Jie Zhang, Fenglong Xie, Huifeng Yun et al. · Annals of the Rheumatic Diseases · 2016 · 114 citations